公开(公告)号：US20230374029A1

公开(公告)日：2023-11-23

申请号：US18004313

申请日：2021-07-06

Applicant: Novartis AG

Inventor： Zhongbo FEI ,  Huanqing JIA ,  Wei LI ,  Jianhua WANG ,  Huangchao YU

IPC: C07D491/107

CPC classification number: C07D491/107

Abstract: The present invention relates to a method for the manufacture of a compound of Formula I or a pharmaceutically acceptable salt, acid co-crystal, hydrate or other solvate thereof, said method comprising reacting a compound of the formula II with a compound of the formula III according to the following reaction scheme: wherein LG, A, n, m and p are as defined in the Summary of the Invention, said manufacture including the manufacture and use of a compound of the formula VI; wherein R1 is a secondary amino protecting group and R5 is unsubstituted or substituted alkyl, unsubstituted or substituted cycloalkyl or unsubstituted or substituted aryl.

公开(公告)号：US20240245694A1

公开(公告)日：2024-07-25

申请号：US18483651

申请日：2023-10-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Markus FUREGATI ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Ziyue HONG ,  Fabio LIMA ,  Fatma LIMAM ,  Henrik MOEBITZ ,  Sandro NOCITO ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Ross Sinclair STRANG ,  Frédéric ZECRI ,  Huangchao YU ,  Yong ZHANG ,  Xinkan YANG ,  Sisi ZHANG ,  Wei LI

IPC: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

CPC classification number: A61K31/5377 ,  A61K31/519 ,  C07D487/14 ,  C07D519/00

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, x, R4, R5, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20240360118A1

公开(公告)日：2024-10-31

申请号：US18506164

申请日：2023-11-10

Applicant: Novartis AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

CPC classification number: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07B2200/13

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I):




wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.

公开(公告)号：US20230046859A1

公开(公告)日：2023-02-16

申请号：US17824407

申请日：2022-05-25

Applicant: NOVARTIS AG

Inventor： Vincent BORDAS ,  Jvan BRUN ,  Andrea DECKER ,  Markus FUREGATI ,  Geoffrey GOGNIAT ,  Wanben GONG ,  Jacques HAMON ,  Jürgen Hans-Hermann HINRICHS ,  Philipp HOLZER ,  Fatma LIMAM ,  Henrik MÖBITZ ,  Sandro NOCITO ,  Simone PLATTNER ,  Niko SCHMIEDEBERG ,  Joseph SCHOEPFER ,  Jessica SOTO ,  Ross Sinclair STRANG ,  Shuping YAO ,  Huangchao YU ,  Frédéric ZECRI ,  Sisi ZHANG

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14

Abstract: The present invention provides a compound, or a pharmaceutically acceptable salt thereof, of formula (I): wherein R1, R2, R3, R4, R5, R26, R27, y, R, M, W, L, V, T, Y, J, K and A are as described herein, therapeutic uses of said compounds, uses of said compounds as research chemicals, a pharmaceutical composition and combinations comprising said compounds, and methods for manufacturing the compounds of the invention.